


on-HN study design

INBRX-106 add-on to pembro in 1L R/M HNSCC with PD-L1 CPS ≥ 20



PS ≥ 20 (by central PD-L1 IHC 22C3 pharmDx) and HPV status (by central p16 IHC, for oropharynx only)

¹: ECOG PS, HPV status, disease status

200 mg Q3W, INBRX-106 0.1 mg/kg Q3W

rate; CPS = combined positive score; cORR = confirmed objective response rate; DoR = duration of response; OS = overall survival; PFS = progression-free survival; QD = once a day; Q3W = every 3 weeks; R = randomization; R/M = recurrent / metastatic; TTCTx = time to chemotherapy; tx = treatment.